Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b conjugate vaccine (Hebei Provincial Center for Disease Control and Prevention)
- Development stage
- Unknown
- Lead developer
- Hebei Provincial Center for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Haemophilus influenzae type b (Hib) conjugate vaccine is a biologic preparation designed to prevent invasive diseases caused by *Haemophilus influenzae* type b, such as meningitis and pneumonia. The vaccine typically consists of the purified polyribosylribitol phosphate (PRP) capsular polysaccharide of Hib chemically conjugated to a carrier protein (such as tetanus toxoid, diphtheria toxoid, or *Neisseria meningitidis* outer membrane protein) to enhance immunogenicity, particularly in infants. This specific freeze-dried formulation has been evaluated in Phase III clinical trials sponsored by the Hebei Center for Disease Control and Prevention to assess its safety and immunogenicity in the pediatric population.
- Other names
- freeze-dried Haemophilus influenzae type B combined vaccineHib conjugate vaccineHaemophilus influenzae type b vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)HLA-DR (Human leukocyte antigen DR)
Beyond the preview
Go deeper on haemophilus influenzae type b conjugate vaccine (Hebei Provincial Center for Disease Control and Prevention).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b conjugate vaccine (Hebei Provincial Center for Disease Control and Prevention).